Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $37.56

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been given an average recommendation of “Moderate Buy” by the nineteen brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $37.56.

Several analysts recently issued reports on the stock. JPMorgan Chase & Co. restated a “neutral” rating and issued a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd. Citigroup increased their price objective on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. BMO Capital Markets dropped their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, January 10th. Finally, The Goldman Sachs Group restated a “sell” rating and set a $9.00 price target on shares of Intellia Therapeutics in a research note on Friday, February 28th.

Intellia Therapeutics Stock Up 1.1 %

NASDAQ:NTLA opened at $8.40 on Friday. Intellia Therapeutics has a 52 week low of $8.11 and a 52 week high of $28.23. The stock’s fifty day moving average is $10.01 and its two-hundred day moving average is $13.90. The company has a market capitalization of $869.54 million, a P/E ratio of -1.54 and a beta of 1.97.

Insider Buying and Selling

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last ninety days, insiders have sold 29,000 shares of company stock worth $352,551. Company insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Several institutional investors have recently modified their holdings of the company. Atria Investments Inc raised its stake in Intellia Therapeutics by 24.3% in the third quarter. Atria Investments Inc now owns 23,099 shares of the company’s stock valued at $475,000 after buying an additional 4,511 shares in the last quarter. KBC Group NV raised its position in shares of Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after acquiring an additional 1,020 shares in the last quarter. Quest Partners LLC raised its position in shares of Intellia Therapeutics by 181.6% during the 3rd quarter. Quest Partners LLC now owns 19,748 shares of the company’s stock worth $406,000 after acquiring an additional 12,734 shares in the last quarter. Jennison Associates LLC lifted its stake in Intellia Therapeutics by 21.6% during the third quarter. Jennison Associates LLC now owns 47,899 shares of the company’s stock worth $984,000 after purchasing an additional 8,497 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in Intellia Therapeutics in the third quarter valued at approximately $580,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.